https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-802008-11-16 00:00:002019-02-15 08:44:32Recent advances in cancer vaccines: an overview
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-502008-11-15 00:00:002019-02-15 09:19:16Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-662008-11-15 00:00:002019-02-15 09:19:17Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-05 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):242-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-05 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):242-502008-11-05 00:00:002019-02-15 08:35:19Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-82008-11-01 00:00:002019-02-15 09:19:15[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-802008-11-01 00:00:002019-02-15 09:23:59Dendritic cell vaccines for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-25 / Cancer Immunol. Immunother. 2009 Jun;58(6):901-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-25 / Cancer Immunol. Immunother. 2009 Jun;58(6):901-132008-10-25 00:00:002019-02-15 08:44:25Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-4032008-10-23 00:00:002019-02-15 09:19:13The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-102008-10-18 00:00:002019-02-15 09:00:15Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
